Pacemakers (Global Market)

• Pacemakers

Pacemakers (Russian market)

Main article: Pacemakers (Russian market)

2024: World pacemaker sales rise to $5.5 billion year-on-year

At the end of 2024, the global pacemaker market reached $5.5 billion. More than 40% of this amount fell on the North American region. Such data are presented in a study by Grand View Research, the results of which TAdviser got acquainted with in early May 2025.

Pacemaker sales show sustained positive dynamics, attributed to the increasing prevalence of cardiovascular disease (CVD), particularly arrhythmia and heart failure. According to the World Health Organization (WHO), CVDs are the leading cause of death worldwide. In the European region, such ailments account for more than 42.5% of all deaths. This means that about 10 thousand people die from CVD every day. Moreover, in Europe, the likelihood of dying from cardiovascular diseases is almost 2.5 times higher for men than for women.

In many cases, an electrocardiostimulator - a small device (an artificial rhythm driver) that creates electrical impulses and directs them into the heart chambers, causing them to contract in a certain order and synchronizing the work of the atria and ventricles - helps prevent death from CVD. The demand for pacemakers increases against the background of an aging population.

A significant market driver is technological advances including the development of MRI compatible pacemakers . Modern devices provide higher efficiency and improve the quality of life of patients. The integration of remote monitoring tools enabling healthcare professionals to monitor pacemaker functions and heart rate in real time enables the provision of personalized care and reduces visits to healthcare facilities. Modern pacemakers support the "on demand" mode of operation: the device automatically monitors heart rate and is activated only if the heart rate goes beyond the thresholds. In turn, cardioverter defibrillators, in addition to rhythm control, can stop arrhythmia attacks and ventricular fibrillation.

The development of the industry is facilitated by government support programs. Many governments and health organizations are working to improve access to advanced cardiac care by offering reimbursement for pacemaker implantation costs, thereby making the procedure more accessible to patients.

In 2024, implantable pacemakers provided the largest share of revenue - 68%. Rhythm driver implantation is indicated in a wide range of diseases such as bradycardia, atrial fibrillation, sinus node weakness syndrome, cardiomyopathy with impaired myocardial contractile function, chronic heart failure. There are also special external pacemakers designed for primary stabilization of the patient and conducting loading functional tests. From a geographical point of view, North America leads, which in 2024 accounted for 43.4% of sales in monetary terms. Globally, the following are named major players:

• Osypka Medical;
• Boston Scientific;
• Zoll Medical;
• Medtronic;
• Biotronik SE & Co. KG№
• MicroPort Scientific;
• Medico S.R.L.;
• Shree Pacetronix;
• Abbott;
• Oscor;
• Lepu Medical Technology.

Analysts at Grand View Research believe that in the future, the CAGR in the market under consideration will be 5.7%. As a result, by 2030, costs could increase to $7.7 billion.^[1]

2023: Worldwide pacemaker sales rise to $3.63 billion in a year

The global pacemaker market reached $3.63 billion in 2023. The demand for such devices is growing due to the increase in the number of cases of cardiovascular diseases and technological advances. This is stated in a study by Market Research Future, the results of which were published at the end of September 2024.

The authors of the report highlight several key factors that contribute to increased sales of pacemakers. According to the World Health Organization (WHO), cardiovascular disease is the leading cause of death in the world. Specialized medical devices, in particular pacemakers, are required to treat some of these ailments. The increase in the supply of such products is due to increased health care costs and the wider use of modern medical services. Pacemakers allow patients with arrhythmias to lead active and healthy lives. In addition, thanks to technological improvements, the functionality of pacemakers is expanding: for example, analysts are talking about the emergence of new generation devices compatible with magnetic resonance imaging (MRI). Other improvements include extended battery life and wireless remote monitoring systems that monitor patient readings and health.

By type, the products used are divided into implantable and external pacemakers: the former dominate the global market. At the same time, devices compatible with MRI provided the largest revenue in 2022. Among the leading players in the industry are named,, Medtronic,, Abbott Laboratories, Boston Scientific Biotronik Lepu Livanova Medical, Shree Pacetronix, Osypka Medical, Medico Spa, Oscor. Large companies spend heavily on R&D to expand their product portfolio and improve device capabilities. One of the main business strategies used by manufacturers is the organization of local production of products to reduce operating costs.

Geographically, the dominant market is North America. This is due to an aging population, and therefore an increase in the number of people with heart problems. In addition, many large players are concentrated in this region, thanks to which the development of technology is accelerated. The European pacemaker market holds the second largest share due to increasing prevalence of heart disease, as well as due to technological developments in medical instruments. At the same time, in the Asia-Pacific region, the highest growth rates are recorded, which is associated with significant development potential. Building a robust health infrastructure to detect and treat cardiovascular diseases is increasingly a priority for these countries.

Restraining factors are the low level of awareness of cardiovascular diseases in developing and undeveloped countries, the high cost of therapy and the increase in the number of recall campaigns of products due to a malfunction. Faster market expansion is also hampered by possible postoperative complications associated with pacemaker installation.

Nevertheless, analysts believe that in the future the industry will show positive dynamics. The CAGR (compound percentage CAGR) is expected to be 3.12%. As a result, by 2032, the volume of the global pacemaker market will rise to $4.81 billion.^[2]

2016: Market size - $8 billion

In November 2017, Stratistics MRC, an analytical company, published the results of a study of the global pacemaker market. Experts expect a twofold increase in sales of this medical device in seven years.

According to Stratistics MRC estimates, in 2016, the total revenue of manufacturers from the sale of pacemakers reached $8.01 billion. By 2023, it will reach almost $15 billion, and the average annual growth rate of the market, thus, will be measured at about 9.3%.

Кардиостимулятор Medtronic

Experts say that one of the main catalysts for the growth of the pacemaker market is the increasing prevalence of cardiovascular diseases. According to the World Health Organization (WHO), released in 2017, 17.7 million people die from such diseases annually in the world, which corresponds to about one third of deaths on a global scale.

The market is fueled by the manufacturers themselves, who are constantly improving pacemakers, including materials and software. By the end of 2017, more such devices use contactless charging, lack antennas and contain fewer ferromagnetic components, making them suitable for magnetic resonance imaging.

Miniature models appear implanted directly into the heart, and biological pacemakers that contain heart cells (or their likeness) extracted from embryonic stem cells or mesenchymal stem cells are also investigated.

At the end of 2016, the following companies were the largest manufacturers of pacemakers (listed in alphabetical order):

• Abbott Laboratories;
• BIOTRONIK SE & Co;
• Boston Scientific;
• Cook Medical;
• Cordis;
• Lepu Medical Technology;
• LivaNova;
• Medico;
• Medtronic;
• Osypka Medical;
• Pacetronix;
• SORIN Group;
• [1]St. Jude Medical;
• USCOME;
• Vitatron;
• Zoll Medical Corporation.^[3]

Notes